新型RAS(ON) 抑制剂zoldonrasib与daraxonrasib可克服实体瘤对传统 KRAS 抑制剂的耐药性 – medfind.link

Larotrectinib is a potent, oral, selective tropomyosin receptor kinase (TRK) inhibitor designed to directly target TRKs (including TRKB, TRKC, and TRK2), shutting down the signaling pathways that lead to the growth of TRK fusion-related tumors. Larotrectinib is a "cancer-agnostic" therapy; it is the world's first oral TRK inhibitor specifically designed for patients with NTRK gene fusion-related cancers. NTRK gene fusions are found in various solid tumor types, including pancreatic cancer, thyroid cancer, salivary gland cancer, breast cancer, colorectal cancer, and lung cancer, especially in some rare cancers such as infantile fibrosarcoma, secretory carcinoma-like breast cancer, and secretory breast cancer...

In 2018, the FDA approved the prescription drug larotrectinib for marketing in the United States for targeting the fusion proteins of neurotrophic tyrosine receptor kinases (NTRK1, NTRK2, NTRK3). Patients must use it strictly as directed by their doctor.

Larotrectinib is a potent, oral, selective tropomyosin receptor kinase (TRK) inhibitor designed to directly target TRKs (including TRKB, TRKC, and TRK2), shutting down the signaling pathways that lead to the growth of TRK fusion-related tumors. Larotrectinib is a "cancer-agnostic" therapy; it is the world's first oral TRK inhibitor specifically designed for patients with NTRK gene fusion-related cancers. NTRK gene fusions are found in various solid tumor types, including pancreatic cancer, thyroid cancer, salivary gland cancer, breast cancer, colorectal cancer, and lung cancer, especially in some rare cancers such as infantile fibrosarcoma, secretory carcinoma-like breast cancer, and secretory breast cancer...